Ardevora Asset Management LLP lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 119,392 shares of the medical research company’s stock after selling 400 shares during the quarter. Ardevora Asset Management LLP’s holdings in Thermo Fisher Scientific were worth $26,719,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Gradient Investments LLC raised its position in shares of Thermo Fisher Scientific by 1,887.5% in the 4th quarter. Gradient Investments LLC now owns 159 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 151 shares in the last quarter. IMS Capital Management acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $53,000. Cornerstone Advisors Inc. raised its position in shares of Thermo Fisher Scientific by 33.3% in the 3rd quarter. Cornerstone Advisors Inc. now owns 332 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 83 shares in the last quarter. Nelson Roberts Investment Advisors LLC raised its position in shares of Thermo Fisher Scientific by 136.4% in the 4th quarter. Nelson Roberts Investment Advisors LLC now owns 364 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 210 shares in the last quarter. Finally, Legacy Financial Advisors Inc. raised its position in shares of Thermo Fisher Scientific by 77.2% in the 4th quarter. Legacy Financial Advisors Inc. now owns 450 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 86.88% of the company’s stock.

Get Thermo Fisher Scientific alerts:

A number of equities analysts have issued reports on TMO shares. UBS Group began coverage on Thermo Fisher Scientific in a research report on Tuesday, October 9th. They issued a “buy” rating and a $295.00 target price on the stock. Citigroup upped their price target on Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, October 10th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $242.00 to $254.00 and gave the company an “overweight” rating in a research report on Wednesday, October 10th. Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Thursday, October 18th. Finally, Robert W. Baird upped their price target on Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a research report on Thursday, October 25th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $275.10.

TMO stock opened at $246.01 on Wednesday. The company has a current ratio of 1.71, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64. The company has a market cap of $98.06 billion, a P/E ratio of 22.12, a PEG ratio of 1.60 and a beta of 1.14. Thermo Fisher Scientific Inc. has a 12-month low of $194.51 and a 12-month high of $253.91.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.06. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The business’s revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.79 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, January 15th. Investors of record on Monday, December 17th were paid a dividend of $0.17 per share. The ex-dividend date of this dividend was Friday, December 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 6.12%.

In related news, Director Tyler Jacks sold 1,100 shares of the company’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $251.98, for a total transaction of $277,178.00. Following the completion of the transaction, the director now directly owns 5,879 shares in the company, valued at approximately $1,481,390.42. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,500 shares of the company’s stock in a transaction on Friday, December 7th. The stock was sold at an average price of $241.45, for a total value of $2,293,775.00. Following the transaction, the chief financial officer now owns 44,124 shares of the company’s stock, valued at $10,653,739.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,607 shares of company stock valued at $7,972,085. 0.49% of the stock is owned by company insiders.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2019/02/06/ardevora-asset-management-llp-has-26-72-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.